Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-controlled, Participant-and-investigator- Blinded, Sponsor Open-label Study to Evaluate the Safety, Tolerability, and Efficacy With Different Dosing Regimens of Subcutaneously Administered MBL949 in Obese Participants With or Without Type 2 Diabetes Mellitus
Conditions
Interventions
MBL949
Placebo
Locations
4
United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Morehead City, North Carolina, United States
Novartis Investigative Site
Knoxville, Tennessee, United States
Novartis Investigative Site
Dallas, Texas, United States
Start Date
February 10, 2022
Primary Completion Date
May 11, 2023
Completion Date
May 11, 2023
Last Updated
October 9, 2024
NCT07351045
NCT07037459
NCT07244458
NCT07508241
NCT05746039
NCT07395687
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions